| Hazard Information | Back Directory | [Uses]
Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH)[1][2]. | [in vivo]
Mipomersen (25 mg/kg; i.p., twice weekly for 11 weeks) affects levels of h-apoB, h-apoB-100, Lp(a) and OxPL/h-apoB[1]. | Animal Model: | Transgenic mice overexpressing human apolipoprotein B-100 (h-apoB mice) or h-apoB-100 plus human apo(a) (Lp(a) mice)[1] | | Dosage: | 25 mg/kg | | Administration: | Intraperitoneal injection; 25 mg/kg, twice weekly for 11 weeks | | Result: | Time-dependently reduced the level of h-apoB-100 in Lp(a) mice and h-apoB in h-apoB mice. |
| [IC 50]
apoB | [References]
[1] Merki E, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation. 2008 Aug 12;118(7):743-53. DOI:10.1161/CIRCULATIONAHA.108.786822
[2] Schaefer EA, et al. Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C. World J Gastroenterol. 2016 Dec 7;22(45):9954-9965. DOI:10.3748/wjg.v22.i45.9954 |
|
|